Characterization of the neutralizing anti‐emicizumab antibody in a patient with hemophilia A and inhibitor

Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM Trial

Jean–Frédéric Colombel, William J. Sandborn, Paul Rutgeerts et al. · Gastroenterology · 2006 · 2.3K citations · Full text

Veterinary Medicine, Immunology, Pharmacotherapy +16

Emicizumab Prophylaxis in Hemophilia A with Inhibitors

Johannes Oldenburg, Johnny Mahlangu, Benjamin Kim et al. · New England Journal of Medicine · 2017 · 1.1K citations · Full text

Medicine, Hematology, Pharmacology +16

Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors

Johnny Mahlangu, Johannes Oldenburg, Ido Paz‐Priel et al. · New England Journal of Medicine · 2018 · 745 citations · Full text

Medicine, Hematology, Pharmacotherapy +14

The immunogenicity of humanized and fully human antibodies

Fiona Harding, Marcia Stickler, Jennifer Razo et al. · mAbs · 2010 · 727 citations · Full text

Pharmacy, Immunology, Molecular Biology +17

Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort

Fabian Schnitzler, Herma H. Fidder, Marc Ferrante et al. · Gut · 2008 · 533 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +14